Abstract
Background: the study aims to evaluate whether high plasma trough levels of the kinase inhibitors (K.I.s) crizotinib, alectinib, osimertinib, dabrafenib, and trametinib were associated with a higher risk of toxicity in non–small-cell lung cancer patients. Methods: In this retrospective cohort study, patients with non–small-cell lung cancer treated with the selected
... read more